Patents Issued in October 24, 2017
-
Patent number: 9796753Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.Type: GrantFiled: April 27, 2016Date of Patent: October 24, 2017Assignee: Purdue Research FoundationInventors: Mark Stanley Cushman, Daniel Edward Beck
-
Patent number: 9796754Abstract: Disclosed herein are non-natural amino acids and dolastatin analogs that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The dolastatin analogs can include a wide range of possible functionalities, but typically have at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid dolastatin analogs and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology use.Type: GrantFiled: May 24, 2012Date of Patent: October 24, 2017Assignee: Ambrx, Inc.Inventors: Zhenwei Miao, Kyle Atkinson, Sandra Biroc, Timothy Buss, Melissa Neal, Vadim Kraynov, Robin Marsden, Jason Pinkstaff, Lillian Skidmore, Ying Sun, Agnieszka Szydlik, Delia Ianina Lopez De Valenta
-
Patent number: 9796755Abstract: The invention relates to methods for treating depression, anxiety, and other related diseases by administering a peptide NMDAR partial agonist.Type: GrantFiled: February 6, 2015Date of Patent: October 24, 2017Assignee: Northwestern UniversityInventor: Joseph R. Moskal
-
Patent number: 9796756Abstract: The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.Type: GrantFiled: December 17, 2015Date of Patent: October 24, 2017Assignee: Arrowhead Pharmaceuticals, Inc.Inventors: Philipp Hadwiger, Torsten Hoffmann, Eric A Kitas, Peter Mohr, Ingo Roehl, Linda Valis, David B Rozema, David L Lewis, Darren H Wakefield
-
Patent number: 9796757Abstract: A peptide, derivative or peptidomimetic that blocks binding of GNA12 to ?SNAP is provided as are methods of using the same to inhibit thrombin-induced von Willebrand Factor secretion and prevent or treat thrombosis.Type: GrantFiled: April 18, 2014Date of Patent: October 24, 2017Assignee: The Board of Trustees of the University of IllinoisInventors: Richard D. Minshall, Luiza Rusu
-
Patent number: 9796758Abstract: A method for producing a polypeptide, includes at least one native ligation step using a peptide functionalized with a selenium group. The selenium peptides and compounds are also described.Type: GrantFiled: March 18, 2013Date of Patent: October 24, 2017Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT PASTEUR DE LILLE, UNIVERSITE LILLE 2 DROIT ET SANTEInventors: Oleg Melnyk, Laurent Raibaut, Nathalie Ollivier
-
Patent number: 9796759Abstract: The present invention provides oligopeptides, in particular, Ang-(1-7) derivatives, and methods for using and producing the same. In one particular embodiment, oligopeptides of the invention have higher blood-brain barrier penetration and/or in vivo half-life compared to the native Ang-(1-7), thereby allowing oligopeptides of the invention to be used in a wide variety of clinical applications including in treatment of cognitive dysfunction and/of impairment.Type: GrantFiled: July 16, 2015Date of Patent: October 24, 2017Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Meredith Hay, John Konhilas, Robin L. Polt, Evan Jones
-
Patent number: 9796760Abstract: The present invention discloses novel non-natural and modified peptides acting as cannabinoid (CB) receptors ligands, especially CB1 and/or CB2, useful as modulators of its activity; they are also described as a kit and a process in vitro for evaluating the binding to CB receptors, uses and pharmaceutical composition for modulating the CB receptors activity. The invention covers the non-natural peptide of SeqID:1 and those having at least 70% similarity related to the same, including as achievements specialty useful of the invention the non-natural peptides of SeqID:2, SeqID:3, SeqID:4, SeqID:5, SeqID:6.Type: GrantFiled: July 12, 2013Date of Patent: October 24, 2017Assignee: Proteimax Biotecnologia LtdaInventor: Andrea Sterman Heimann
-
Patent number: 9796761Abstract: The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.Type: GrantFiled: July 12, 2010Date of Patent: October 24, 2017Assignees: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE, GLYCOBIOMARKER LEADING INNOVATION CO., LTD.Inventors: Hisashi Narimatsu, Jun Hirabayashi, Yuzuru Ikehara, Takashi Angata, Hiroyuki Kaji, Atsushi Kuno, Takashi Ohkura, Toshihide Shikanai, Maki Sogabe, Akira Togayachi, Makoto Ochou, Yasuhito Tanaka, Masashi Mizokami
-
Patent number: 9796762Abstract: The present invention relates to Roseburia flagellin, and/or a polynucleotide sequence encoding said Roseburia flagellin, and/or a vector comprising said polynucleotide sequence, and/or a host cell, including bacteria, comprising said vector, and/or a host cell, including bacteria, comprising said polynucleotide sequence, for use in modulating the inflammation of a tissue or an organ in a subject.Type: GrantFiled: April 10, 2014Date of Patent: October 24, 2017Assignee: 4D Pharma Research LimitedInventors: Denise Kelly, Angela Patterson, Edouard Monnais, Imke Mulder
-
Patent number: 9796763Abstract: An isolated polynucleotide is provided. The isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide of a Type II reaction center of a photosynthetic organism, the nucleic acid sequence being capable of imparting the type II reaction center with an activity under a temperature range different than that of the type II reaction center endogenous to the photosynthetic organism. Also provided are methods of using the sequences for generating photosynthetic organisms or tailor-made thermotolerance.Type: GrantFiled: December 2, 2013Date of Patent: October 24, 2017Inventors: Avigdor Scherz, Oksana Shlyk-Kerner, Ilan Samish, David Kaftan, Jorge Dinamarca
-
Patent number: 9796764Abstract: The present invention relates to cyclotides and cyclotide-encoding genes from the Fabaceae plant family, and to the expression of cyclotides in Fabaceae. The present invention further relates to isolated nucleic acids configured to express cyclotides comprising heterologous peptide grafts in plants of the Fabaceae family.Type: GrantFiled: March 23, 2012Date of Patent: October 24, 2017Assignees: The University of Queensland, Commonwealth Scientific and Industrial Research OrganisationInventors: Aaron G. Poth, Michelle Colgrave, Russell Lyons, David Craik
-
Patent number: 9796765Abstract: [Problem] The purpose of the present invention is to stably supply high-quality and highly uniform Wisteria floribunda agglutinin (WFA) that recognizes biologically important sugar-chain markers, to elucidate the sugar-chain recognition activity in detail, and to furthermore increase the specificity of the sugar-chain recognition activity. [Solution] The present invention involves the development of a technique for cloning genes for coding Wisteria floribunda agglutinin (WFA) and producing recombinant WFA having the same sugar-chain recognition activity as natural WFA from transformed bacteria. Natural WFA is reduced to thereby manufacture a reduced WFA monomer for specifically recognizing terminal GalNAc residue. A recombinant monomer WFA for recognizing LDN (GalNAc?1, 4GlcNAc) sugar chain, which is important as a diagnostic marker among sugar chains having a terminal GalNAc residue, is manufactured by introducing cysteine mutation to recombinant WFA or by C-terminal-side amino acid deletion.Type: GrantFiled: December 18, 2013Date of Patent: October 24, 2017Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGYInventors: Takashi Sato, Yasunori Chiba, Hiroaki Tateno, Hiroyuki Kaji, Masanori Goto, Hisashi Narimatsu
-
Patent number: 9796766Abstract: Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted NaV1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of NaV1.7 and/or NaV1.3. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.Type: GrantFiled: April 20, 2016Date of Patent: October 24, 2017Assignee: AMGEN INC.Inventors: Justin K. Murray, Leslie P. Miranda, Stefan I. McDonough
-
Patent number: 9796767Abstract: The present invention provides a nucleic acid molecule which encodes a polypeptide consisting of two methionine residues as the first and second N-terminal amino acid residues linked via a peptide bond to a mature eukaryotic histone. The present invention furthermore relates to a vector containing said nucleic acid molecule, a host transformed with said vector, polypeptides encoded by the nucleic acid molecule and pharmaceutical and diagnostic compositions. The present invention also relates to the use of the nucleic acid molecule, vectors, hosts and the polypeptide of the invention for the preparation of a composition for the treatment of diseases. Furthermore, the present invention relates to a method of testing for the presence of the nucleic acid molecule or the polypeptide in a sample and to a kit.Type: GrantFiled: January 19, 2016Date of Patent: October 24, 2017Assignee: Symbiotec Genellschaft zur Erforschung auf dem Geibeit der Biotechnologie, MBHInventors: Peter Gross, Hans Jornvall, Grazyna Formicka-Zeppezauer, Michael Zeppezauer, Michel Thiry
-
Patent number: 9796768Abstract: The present invention relates to the ability of specialized non-naturally occurring peptides to bind to sodium channels and inhibit activation of the sodium channels. The invention further relates to methods for regulating of sodium absorption and fluid volume and treating disorders responsive to modulating sodium absorption by modulating the binding of specialized non-naturally occurring peptides to sodium channels.Type: GrantFiled: April 21, 2017Date of Patent: October 24, 2017Assignees: Spryx Biosciences, Inc., The University of North Carolina at Chapel HillInventors: Robert Tarran, Dale J. Christensen
-
Patent number: 9796769Abstract: A method of preparing a crosslinked, collagen-based medical scaffold is provided, comprising: (a) immersing a sample of fibrous and/or non-fibrous collagen in a buffered acidic, aqueous solution comprising an alcohol; (b) contacting the collagen in solution with a catalytic component comprising 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride for a time at least sufficient to effect reaction between amino and carboxyl groups present on the collagen and to yield crosslinked collagen that is resistant to pronase degradation; and (c) drying the crosslinked collagen to yield a porous, crosslinked collagen article wherein the porous, crosslinked collagen article demonstrates a pore size of 10-500 microns. Also provided are bioactive collagen medical scaffolds for wound care dressings, hernia repair prosthetics, and surgical incision closure members, prepared using the method above.Type: GrantFiled: September 30, 2013Date of Patent: October 24, 2017Assignee: ENSION INC.Inventors: Ali Hussain, Patrick Cahalan, Linda Cahalan
-
Patent number: 9796770Abstract: The invention relates to an immunoglobulin composition reduced in thrombogenic agents and to methods for its preparation. One method comprises subjecting an immunoglobulin containing solution to a negative cation exchanger chromatography at a pH in the range of higher than 3.8 to equal to or lower than 5.3. The solution can also be subjected to a negative anion exchanger chromatography at a pH in the range of 7 to 8.2.Type: GrantFiled: April 3, 2015Date of Patent: October 24, 2017Assignee: Omrix Biopharmaceuticals Ltd.Inventors: Roni Mintz, Oleg Belyaev, Israel Nur, Liliana Bar, Roberto Meidler
-
Patent number: 9796771Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: GrantFiled: November 22, 2016Date of Patent: October 24, 2017Assignee: Institute for Research in BiomedicineInventors: Antonio Lanzavecchia, Annalisa Macagno
-
Patent number: 9796772Abstract: The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hCMV, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hCMV gene UL products. The invention also relates to immortalized B cells that produce, and to epitopes that bind to, such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, prevention, and therapy of disease.Type: GrantFiled: November 22, 2016Date of Patent: October 24, 2017Assignee: Institute for Research in BiomedicineInventors: Antonio Lanzavecchia, Annalisa MacAgno
-
Patent number: 9796773Abstract: This invention features polypeptides, variants thereof, and fragments thereof useful in eliciting an immune response (e.g., neutralizing antibodies) against a broad spectrum of HIV-1 isolates. The polypeptides, variants, and fragments include a portion of the gp120 V2 domain of HIV-1. The polypeptides, variants, and fragments display an epitope that is recognized by at least one antibody which neutralizes at least one HIV-1 primary isolate. This invention also features nucleic acid sequences encoding those polypeptides. In addition, the invention provides methods of screening for inhibitors of HIV-1 entry into cells, as well as methods of treatment using the inhibitors.Type: GrantFiled: August 19, 2014Date of Patent: October 24, 2017Assignee: Rutgers, The State University of New JerseyInventor: Abraham Pinter
-
Patent number: 9796774Abstract: The present application relates novel HIV-1 broadly neutralizing antibodies. The antibodies of the present invention are further characterized by their ability to bind epitopes from the Env proteins. The invention also provides light and heavy chain variable region sequences. Compositions for prophylaxis, diagnosis and treatment of HIV infection are provided.Type: GrantFiled: April 19, 2016Date of Patent: October 24, 2017Assignees: INTERNATIONAL AIDS VACCINE INITIATIVE, THE SCRIPPS RESEARCH INSTITUTEInventors: John Mascola, Dennis R. Burton, Wayne Koff, Peter Kwong, Gary Nabel, Sanjay K. Phogat, Pascal Raymond Georges Poignard, Melissa Danielle De Jean St. Marcel Simek-Lemos, Xueling Wu, Tongqing Zhou, Zhi-Yong Yang
-
Patent number: 9796775Abstract: This invention relates to a method for detecting pancreatic cancer using novel tumor markers. Specifically, the invention provides a method for detecting pancreatic cancer comprising measuring the presence or an amount of a polypeptide having an reactivity of binding via an antigen-antibody reaction to an antibody against CAPRIN-1 protein in a sample separated from a subject, and to a reagent or kit for detecting pancreatic cancer comprising a CAPRIN-1 protein or a fragment thereof, an antibody against the same, or a polynucleotide encoding the same.Type: GrantFiled: August 3, 2012Date of Patent: October 24, 2017Assignee: TORAY INDUSTRIES, INC.Inventors: Takayoshi Ido, Fumiyoshi Okano
-
Patent number: 9796776Abstract: The present disclosure relates to antibodies and polynucleotides encoding the same, which may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement Factor Bb. Specifically, the disclosure is related to anti-complement Factor Bb antibodies.Type: GrantFiled: February 25, 2015Date of Patent: October 24, 2017Assignee: Allergan, Inc.Inventors: Yanbin Liang, Chen Li, Iris Lee, Victor M. Guzman
-
Patent number: 9796777Abstract: The present invention relates to isolated protein sequences that correspond to cell binding peptides, fragments, neo-structures and/or neo-epitopes of a normally occurring serum protein present in human tissue, wherein the peptide, fragment, neo-structure and/or neo-epitope has an immunoregulatory activity and is the result of either an enhanced proteolytic activity and/or conformational changes in a tissue, or a malignant tumor. In the present patent application, a common structure of several of these peptides, fragments, neo-structures and/or neo-epitopes, having immunoregulatory activity by binding to receptors on immune cells, has been identified. The present invention further also relates to monoclonal and/or polyclonal antibodies directed to a cell binding fragment of a normally occurring serum protein present in human tissue, as described above.Type: GrantFiled: July 31, 2015Date of Patent: October 24, 2017Assignee: CANIMGUIDE THERAPEUTICS ABInventors: Leif Håkansson, Birgitta Clinchy
-
Patent number: 9796778Abstract: Disclosed herein are novel pathological form of TDP-43, monoclonal antibodies against such pathological form of TDP-43, and uses thereof. The novel pathological form of TDP-43 is characterized in having a spherical particle size of about 2 to 400 nm in diameter.Type: GrantFiled: September 15, 2015Date of Patent: October 24, 2017Assignee: Academia SinicaInventor: Yun-Ru Chen
-
Patent number: 9796779Abstract: Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.Type: GrantFiled: October 6, 2015Date of Patent: October 24, 2017Assignee: MedImmune LimitedInventors: Olivia Raeber, Gadi Gazit-Bornstein, Xiao-Dong Yang, Susan Ann Cartlidge, David William Tonge
-
Patent number: 9796780Abstract: The invention provides methods of treating diseases, disorders or injuries involving motor neuron survival and axonal growth, including amylotrophic lateral sclerosis, by the administration of a LINGO-2 antagonist. An exemplary method for promoting survival of a motor neuron, comprising contacting said motor neuron with an effective amount of a composition comprising a LINGO-2 antagonist selected from the group consisting of: (i) a soluble LINGO-2 polypeptide; (ii) a LINGO-2 antibody or antigen-binding fragment thereof; (iii) a LINGO-2 antagonist polynucleotide; (iv) a LINGO-2 aptamer; and (v) a combination of two or more of said LINGO-2 antagonists.Type: GrantFiled: May 14, 2013Date of Patent: October 24, 2017Assignee: Biogen MA Inc.Inventors: Sha Mi, R. Blake Pepinsky
-
Patent number: 9796781Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.Type: GrantFiled: October 29, 2015Date of Patent: October 24, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Ravindra Majeti, Irving L. Weissman
-
Patent number: 9796782Abstract: The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11R?) and uses thereof, e.g., in therapy.Type: GrantFiled: October 19, 2015Date of Patent: October 24, 2017Assignee: CSL LIMITEDInventors: Kirsten Edwards, Matthew Hardy, Veronika Rayzman, Michael Wilson
-
Patent number: 9796783Abstract: The present disclosure provides an antibody or an antigen-binding fragment thereof with binding specificity for human interleukin-1 receptor accessory protein (IL1 RAP) wherein the antibody or antigen-binding fragment is capable of inhibiting the binding of antibody ‘CAN04’ to human IL1 RAP. The disclosure further provides the use of such antibodies or an antigen-binding fragments in the treatment and/or diagnosis of IL-1 associated diseases and conditions, including cancers such as acute myeloid leukemia and melanoma.Type: GrantFiled: September 2, 2016Date of Patent: October 24, 2017Assignee: Cantargia ABInventors: Helena Ågerstam, Thoas Fioretos, Marcus Järås, Cecilia Ann-Christin Malmborg Hager, Kjell Sjöström, Agneta Svedberg, Karin von Wachenfeldt
-
Patent number: 9796784Abstract: The present invention features methods and compositions for the generation and use of conformation-specific antibodies or fragments thereof.Type: GrantFiled: July 7, 2014Date of Patent: October 24, 2017Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Kun Ping Lu, Xiao Zhen Zhou
-
Patent number: 9796785Abstract: The purpose of the present invention is to provide a novel monoclonal antibody having high affinity and that strictly recognizes, as a sugar chain epitope, only a “Sia?2,6Gal?1,4GlcNAc (6?-Sialyl-LacNAc): CDw75” sugar chain structure, being a molecular target for diagnosis of the malignancy of tumors. An anti-CDw75 monoclonal antibody is provided that recognizes “CDw75” sugar chain structures but does not recognize similar sugar chain structures indicated by “Gal?1,4GlcNAc”, “Sia?2,3Gal?1,4GlcNAc”, or “Sia?2,6Gal?1,4Glc”, by using a glycolipid antigen bonding a carrier lipid compound “HOCH2CH(NH—CO—(CH2)22—CH3)—(CH2)9—CH3 (C12L)” developed by the inventors to a “CDw75” sugar chain. The obtained anti-CDw75 monoclonal antibody is an excellent detection drug for B-cell lymphoma, gastric cancer, or colorectal cancer, an excellent diagnostic agent for tumor malignancy, etc.Type: GrantFiled: May 2, 2014Date of Patent: October 24, 2017Assignee: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGYInventor: Tetsuya Okuda
-
Patent number: 9796786Abstract: The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (VH) domain and/or a variable light chain (VL) domain, and wherein (a) the VH domain comprises complementarity determining regions (CDRs) selected from the group consisting of: a CDR1 sequence having identity to the sequence of SEQ ID NO: 7; a CDR2 sequence having identity to the sequence of SEQ ID NO: 8; and a CDR3 sequence having identity to the sequence of SEQ ID NO: 9 or 10; and/or (b) the VL domain comprises CDRs selected from the group consisting of: a CDR4 sequence having identity to the sequence of SEQ ID NO: 11; a CDR5 sequence having identity to the sequence of SEQ ID NO: 12; a CDR6 sequence having identity to the sequence of SEQ ID NO: 13.Type: GrantFiled: August 8, 2012Date of Patent: October 24, 2017Assignees: ATHERA BIOTECHNOLOGIES AB, DYAX CORP.Inventors: Knut Pettersson, Ola Camber, Dan Sexton, Andrew E. Nixon
-
Patent number: 9796787Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.Type: GrantFiled: October 1, 2015Date of Patent: October 24, 2017Assignee: Vaccibody A/SInventors: Bjarne Bogen, Agnete Brunsvik Fredriksen, Inger Sandlie
-
Patent number: 9796788Abstract: A genetically modified mouse is provided, wherein the mouse expresses an immunoglobulin light chain repertoire characterized by a limited number of light chain variable domains. Mice are provided that present a choice of two human light chain variable gene segments such that the immunoglobulin light chains expresses by the mouse comprise one of the two human light chain variable gene segments. Methods for making bispecific antibodies having universal light chains using mice as described herein, including human light chain variable regions, are provided. Methods for making human variable regions suitable for use in multispecific binding proteins, e.g., bispecific antibodies, and host cells are provided.Type: GrantFiled: March 13, 2013Date of Patent: October 24, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: John McWhirter, Lynn MacDonald, Sean Stevens, Andrew J. Murphy
-
Patent number: 9796789Abstract: The present invention relates to a biomemory device, comprising (a) a substrate; and (b) a heterolayer comprising a protein having a redox potential and an inorganic particle; wherein the heterolayer is immobilized on the substrate. By applying inorganic particles, the present invention provides a biomemory device capable of enhancing low current signals detected electron transfer between biomolecules and substrates up to at least five (5) times greater signals. The present invention is capable of controlling the redox states with help of redox potentials of proteins depending on applied potential. The present invention provides a new-concept biomemory device as an information storage device based on the principle of electron transfer of a naturally occurring biomolecule.Type: GrantFiled: August 1, 2012Date of Patent: October 24, 2017Assignee: INDUSTRY-UNIVERSITY COOPERATION FOUNDATION SOGANG UNIVERSITYInventors: Jeong Woo Choi, Taek Lee, Jun Hong Min
-
Patent number: 9796790Abstract: A liquid composition contains a cellulosic material constituted by a material containing at least one of cellulose and a cellulose derivative, and an ionic liquid having a functional group with reactivity. It is preferred that the ionic liquid has an imidazolium salt structure. It is also preferred that the functional group with reactivity contains a carbon-carbon double bond.Type: GrantFiled: November 12, 2015Date of Patent: October 24, 2017Assignee: Seiko Epson CorporationInventor: Toshihiro Otake
-
Patent number: 9796791Abstract: Regioselectively substituted cellulose esters having a plurality of aryl-acyl substituents and a plurality of alkyl-acyl substituents are disclosed along with methods for making the same. Such cellulose esters may be suitable for use in optical films, such as optical films having certain Nz values, ?A optical films, and/or +C optical films. Optical films prepared employing such cellulose esters have a variety of commercial applications, such as, for example, as compensation films in liquid crystal displays and/or waveplates in creating circular polarized light used in 3-D technology.Type: GrantFiled: March 1, 2012Date of Patent: October 24, 2017Assignee: EASTMAN CHEMICAL COMPANYInventors: Charles Michael Buchanan, Michael Eugene Donelson, Elizabeth Guzman-Morales, Peter Borden Mackenzie, Bin Wang
-
Patent number: 9796792Abstract: Compositions comprising metal ions or clusters such as ferrous and/or ferric iron compounds or magnesium, zinc, lanthanum and other metal ion compounds and fiber components such as gum Arabic in a complex, methods for preparing such compositions of matter, and the use thereof for treatment of adsorbing certain accessible targets in the gastrointestinal tract and in an extracorporeal system, are provided herein.Type: GrantFiled: March 4, 2014Date of Patent: October 24, 2017Assignee: Vidasym, Inc.Inventor: Jinshyun Ruth Wu-Wong
-
Patent number: 9796793Abstract: The present invention is a multilayered composite comprising porous metal oxide particles that are covalently bonded by way of inorganic ether groups to one or more sites of a first polyhydroxyl-functionalized polymer. This first polymer is in turn covalently bonded by way of inorganic ether groups to one or more sites of a second polyhydroxyl-functionalized polymer. The multilayered composites can be prepared by contacting porous inorganic-oxide particles with a sufficient amount of OH-reactive crosslinking agent to form metal oxide particles imbibed with the crosslinking agent, and then contacting the inorganic-oxide particles with a solution of polyhydroxyl-functionalized polymer under reactive conditions.Type: GrantFiled: September 5, 2014Date of Patent: October 24, 2017Assignees: The Regents of the University of California, Dow Global Technologies LLC, Rohm and Haas CompanyInventors: Joseph Jankolovits, Alexander S. Katz, Oz M. Gazit, James C. Bohling, John A. Roper, III
-
Patent number: 9796794Abstract: The present invention relates to ionomers comprising a reaction product of the reaction between a) a halogenated isoolefin copolymer and b) a nucleophile having no pendant vinyl group and a nucleophile comprising at least one pendant vinyl group. The present invention also relates to a method of preparing and curing these ionomers.Type: GrantFiled: December 18, 2013Date of Patent: October 24, 2017Assignee: LANXSS, Inc.Inventors: Dana K. Adkinson, Jacob Rawski, Sean Malmberg, Gregory J. E. Davidson
-
Patent number: 9796795Abstract: This invention relates to a compound represented by the formula: TyCp?mMGnXq wherein: Cp? is a tetrahydroindacenyl group which may be substituted or unsubstituted, provided that when Cp? is tetrahydro-s-indacenyl: 1) the 3 and/or 4 positions are not aryl or substituted aryl, 2) the 3 position is not directly bonded to a group 15 or 16 heteroatom, 3) there are no additional rings fused to the tetrahydroindacenyl ligand, 4) T is not bonded to the 2-position, and 5) the 5, 6, or 7-position is geminally disubstituted; M is a group 3, 4, 5, or 6 transition metal; G is a heteroatom group represented by the formula JRiz where J is N, P, O or S, Ri is a C1 to C20 hydrocarbyl group, and z is 1 or 2; T is a bridging group; y is 0 or 1; X is a leaving group; m=1; n=1, 2 or 3; q=1, 2 or 3, and the sum of m+n+q is equal to the oxidation state of the transition metal.Type: GrantFiled: May 3, 2016Date of Patent: October 24, 2017Assignee: ExxonMobil Chemical Patents Inc.Inventors: Jo Ann M. Canich, Crisita Carmen H. Atienza, Vyatcheslav V. Izmer, Dmitry S. Kononovich, Alexander Z. Voskoboynikov
-
Patent number: 9796796Abstract: A catalyst composition for the polymerization of propylene is provided. The catalyst composition includes one or more Ziegler-Natta procatalyst compositions having one or more transition metal compounds and an internal electron donor, one or more aluminum containing cocatalysts, and a selectivity control agent (SCA). The SCA is a mixture of an activity limiting agent (ALA) and selectivity determining agent (SDA) such as a non-silane composition. The present catalyst composition is silane-free, has high catalyst activity and high stereoselectivity, and is self-extinguishing.Type: GrantFiled: August 20, 2008Date of Patent: October 24, 2017Assignee: W. R. Grace & Co.-Conn.Inventors: Linfeng Chen, Richard E. Campbell, Jr.
-
Patent number: 9796797Abstract: Disclosed are polyethylene, chlorinated polyethylene thereof and a molded article produced from the chlorinated polyethylene. More specifically, disclosed are polyethylene for preparation of chlorinated polyethylene, the polyethylene having a molecular weight distribution (MWD) of 5 or less, a melting index (5.0 kg) of 0.1 to 10 dg/min, a weight average molecular weight of 50,000 to 300,000 g/mol, a melting temperature of 125 to 135° C., a wax content of 0.0001 to 3% by weight or 0.01 to 0.3% by weight and a density of 0.94 g/cm3 or more, chlorinated polyethylene thereof and a molded article produced from the chlorinated polyethylene.Type: GrantFiled: April 17, 2014Date of Patent: October 24, 2017Assignee: LG Chem, Ltd.Inventors: Soung Hun Yoo, Geun Yeol Bae, Sang Rok Do
-
Patent number: 9796798Abstract: A method comprising a) calcining a silica support at temperature in the range of from about 100° C. to about 500° C. to form a precalcined silica support; b) contacting the precalcined silica support with a titanium alkoxide to form a titanated support; c) subsequent to b), contacting the titanated support with a polyol to form a polyol associated titanated support (PATS); d) contacting at least one of the silica support, pre-calcined silica support, the titanated support, the PATS, or combinations thereof with a chromium-containing compound to form a polymerization catalyst precursor; e) drying the polymerization catalyst precursor to form a dried polymerization catalyst precursor; and f) calcining the dried polymerization catalyst precursor to produce a polymerization catalyst, wherein less than about 0.1 wt. % of a highly reactive volatile organic compound (HRVOC) is emitted during the calcining of the dried polymerization catalyst precursor.Type: GrantFiled: September 30, 2016Date of Patent: October 24, 2017Assignee: Chevron Phillips Chemical Company, LPInventors: Jeremy M. Praetorius, Eric D. Schwerdtfeger, Max P. McDaniel, Ted H. Cymbaluk, Connor D. Boxell, Kathy S. Collins, Alan L. Solenberger
-
Patent number: 9796799Abstract: [Object] To provide transition metal compounds with excellent catalytic activity which can afford olefin polymers such as propylene polymers that have high stereoregularity and high molecular weight and may be easily crystallized into a ?-phase. [Solution] The transition metal compound is represented by General Formula [I] or is an enantiomer thereof: [in Formula [I], R1, R3, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15 and R16 are each independently a hydrogen atom, a hydrocarbon group, a hetero atom-containing hydrocarbon group, or a silicon-containing group; R2 is a hydrocarbon group, a hetero atom-containing hydrocarbon group, or a silicon-containing group; R4 is a hydrogen atom; any two substituents of the substituents R1 to R16 except R4 may be bonded to each other to form a ring; M is a Group IV transition metal; Q is a structure such as a halogen atom; and j is an integer of 1 to 4].Type: GrantFiled: June 28, 2016Date of Patent: October 24, 2017Assignee: MITSUI CHEMICALS, INC.Inventor: Munehito Funaya
-
Patent number: 9796800Abstract: A method for producing a polydiene, the method comprising of combining a lanthanide compound, an alkylating agent, a halogen source, and optionally conjugated diene monomer to form an active preformed catalyst; independent of step (i), introducing an amine with conjugated diene monomer to be polymerized; independent of step (i), introducing the active preformed catalyst to the conjugated diene monomer to be polymerized to form an active polymerization mixture, where the active polymerization mixture includes less than 10% by weight, based on the total weight of the active polymerization mixture, of a solvent; and allowing the monomer to be polymerized to polymerize in the presence of the amine.Type: GrantFiled: December 22, 2015Date of Patent: October 24, 2017Assignee: Bridgestone CorporationInventors: Kevin M. McCauley, Steven Luo
-
Patent number: 9796801Abstract: The polymerization catalyst composition includes: Component (A): a rare earth element compound of formula (i): M-(NQ1)(NQ2)(NQ3) (where M is at least one selected from lanthanoid, scandium, and yttrium, and NQ1, NQ2 and NQ3 are amide groups and each have a M-N bond; Component (B): a hydrocarbyl aluminoxane compound having a C1-20 hydrocarbon group; and Component (C): a compound of formula (X): YR1aR2bR3c (where Y is a metal selected from groups 1, 2, 12 and 13 in a periodic table, R1 and R2 are C1-10 hydrocarbon groups or hydrogen atoms and R3 is a C1-10 hydrocarbon group).Type: GrantFiled: February 14, 2014Date of Patent: October 24, 2017Assignee: BRIDGESTONE CORPORATIONInventors: Shojiro Kaita, Satoru Tamaki
-
Patent number: 9796802Abstract: The present invention is directed to resins made from cashew nutshell liquid and vinyl hydrocarbons and processes for manufacturing the resins. These resins exhibit lower viscosity than the phenol-based homologs. They also exhibit good compatibility with a wide range of solvents, mineral and natural oils, epoxy curing agents, liquid epoxy resins, and polymers, which make them suitable additives as non-reactive diluents for solvent-free coating formulations; tackifiers for structural adhesive, pressure sensitive and hot-melt adhesives; stabilizers for lubricants, fuel and polymer formulations; plasticizers for thermoplastic polymers and processing aid for rubber compounding and stabilizers for respective rubber artifacts. These resins are also valuable precursors for the manufacture of epoxy resins and polyols for coating, adhesive and composite omulations exhibiting ameliorated performance in water repellency, anti-corrosion, and fast hardness development during cure.Type: GrantFiled: November 25, 2015Date of Patent: October 24, 2017Assignee: CARDOLITE CORPORATIONInventors: Mauricio Pinto, Hong Xu, Anbazhagan Natesh, Junhong Wei